Agenus’ (AGEN) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Agenus (NASDAQ:AGEN) in a research report sent to investors on Wednesday,Benzinga reports.

Agenus Stock Performance

Agenus stock opened at $1.86 on Wednesday. Agenus has a 1 year low of $1.65 and a 1 year high of $19.69. The firm has a 50 day moving average price of $3.17 and a 200 day moving average price of $3.80. The company has a market cap of $43.63 million, a price-to-earnings ratio of -0.17 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last released its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.36) by $0.32. The company had revenue of $26.84 million during the quarter, compared to analysts’ expectations of $30.09 million. Sell-side analysts predict that Agenus will post -12.55 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Deutsche Bank AG lifted its position in Agenus by 538.4% during the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 51,566 shares in the last quarter. Corton Capital Inc. acquired a new position in Agenus during the fourth quarter valued at approximately $36,000. Bank of America Corp DE lifted its position in Agenus by 34.0% during the fourth quarter. Bank of America Corp DE now owns 107,123 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 27,157 shares in the last quarter. Jane Street Group LLC lifted its position in Agenus by 97.6% during the fourth quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock valued at $290,000 after buying an additional 52,215 shares in the last quarter. Finally, B. Riley Financial Inc. acquired a new position in Agenus during the fourth quarter valued at approximately $2,074,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.